Do you want to read an article? Please log in or register.
Remission and low disease activity in a cohort of real-life patients with rheumatoid arthritis treated with first-line antitumour necrosis factor
Rheumatoid Arthritis
Related content
Rheumatoid Arthritis
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study
Ann Rheum Dis.
Pappas DA, St John G, Etzel CJ, Fiore S, Blachley T, Kimura T, Punekar R, Emeanuru K, Choi J, Boklage S, Kremer JM
doi: 10.1136/annrheumdis-2020-217209.
Psoriatic Arthritis
Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab
Rheumatology (Oxford).
Coates LC, Rahman P, Psaradellis E, Rampakakis E, Osborne B, Lehman AJ,
Nantel F
doi: 10.1093/rheumatology/key359.
Rheumatoid Arthritis
Remission vs low disease activity: function, quality of life and structural outcomes in the Early Rheumatoid Arthritis Study and Network
Rheumatology (Oxford).
Nikiphorou E, Norton SJ, Carpenter L, Walsh DA, Creamer P, Dixey J, Young A, Kiely PDW
doi: 10.1093/rheumatology/kez461.
COMMENTED
PsoriasisRheumatoid Arthritis
Anti-tumour necrosis factor-α therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
★ 3
Recommended and commented by
PD Dr Luc Biedermann, Faculty Member
doi: 10.1016/S2468-1253(19)30362-0.
COMMENTED
Rheumatoid Arthritis
Is treat-to-target really working in rheumatoid arthritis? a longitudinal analysis of a cohort of patients treated in daily practice (RA BIODAM)
★ 2
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
doi: 10.1136/annrheumdis-2019-216819.
Psoriatic Arthritis
Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries
Ann Rheum Dis.
Gorlier C, Orbai AM, Puyraimond-Zemmour D, Coates LC, Kiltz U, Leung YY, Palominos P, Cañete JD, Scrivo R, Balanescu A, Dernis E, Tälli S, Ruyssen-Witrand A, Soubrier M, Aydin SZ, Eder L, Gaydukova I, Lubrano E, Kalyoncu U, Richette P, Husni ME, de Wit M, Smolen JS, Gossec L
doi: 10.1136/annrheumdis-2018-214140.
Rheumatoid Arthritis
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Arthritis Rheumatol.
Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, Graham NM, van Hoogstraten H, Bauer D, Burmester GR
doi: 10.1002/art.39944.
Rheumatoid Arthritis
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Clin Rheumatol.
Mueller RB, Graninger W, Sidiropoulos P, Goger C, von Kempis J
doi: 10.1007/s10067-017-3779-2.
Rheumatoid Arthritis
Effectiveness and safety of anti-tumour necrosis factor therapy with certolizumab pegol observed in real-life rheumatoid arthritis patients in Germany: results from the non-interventional FαsT study
Clin Exp Rheumatol.
Burmester G, Nüsslein H,
von Hinüber U, Detert J, Richter C, Kumke T, Leunikava I, Lendl U, Fricke D, Müller-Ladner U